Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna swings to Q4 loss after nearly 66% drop in revenue
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna stock down pre-market on mixed 2024 earnings
Moderna ( MRNA) reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday. Moderna's stock was down 4.5% in pre-market trading on the earnings ...
Hosted on MSN20h
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
Moderna price target lowered to $25 from $35 at Wolfe Research
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Moderna posts bigger loss than expected as vaccine maker scales down manufacturing
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...